OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 110 participants.

Also called NCT04789239

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04789239
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Sweden (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04789239. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
Acronym
OPRA-HF
Condition
Heart Failure
Condition
Hyperkalemia
Intervention (Drug)
Sodium zirconium cyclosilicate
Intervention (Other)
Placebo
Lead sponsor
Michael Fu (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
Göteborg University (class: other)

Record details

Record id
cardio:ct-nct04789239
Content hash
c3ea37fa9d82828ae3c155940a102d79b1b56f1f743ea912e92c7f1d3ef67cdf